0K6R Stock Chart & Stats
$153.99
$1.20(0.68%)
At close: 4:00 PM EDT
$153.99
$1.20(0.68%)
Day’s Range― - ―
52-Week Range$118.72 - $190.00
Previous CloseN/A
Volume1.18K
Average Volume (3M)1.26K
Market Cap
$14.37B
Enterprise Value$17.57B
Total Cash (Recent Filing)$389.80M
Total Debt (Recent Filing)$401.80M
Price to Earnings (P/E)20.1
Beta0.63
Next Earnings
Nov 02, 2026EPS Estimate
1.91Next Dividend Ex-DateN/A
Dividend Yield0.32%
Share Statistics
EPS (TTM)7.05
Shares Outstanding101,649,180
10 Day Avg. Volume2,364
30 Day Avg. Volume1,256
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)4.34
Price to Sales (P/S)4.93
P/FCF Ratio18.85
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue5.21
Enterprise Value/Gross Profit5.32
Enterprise Value/Ebitda19.14
Forecast
1Y Price Target
$207.28Price Target Upside34.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering26
EPS Forecast (FY)7.05
Revenue Forecast (FY)$3.90B
Bulls Say, Bears Say
Bulls Say
Strong Revenue, Profitability, And Cash GenerationNeurocrine combines substantial revenue growth with high and improving profitability, while free cash flow closely tracks earnings. This supports internal funding for research, commercialization, and strategic investment, giving the company durable financial capacity over the next several quarters.
INGREZZA And CRENESSITY Commercial MomentumThe core portfolio is showing sustained adoption across established and newer therapies. INGREZZA provides a growing revenue base, while CRENESSITY’s patient penetration, persistency, and reimbursement support continued expansion and reduce reliance on a single product over time.
Pipeline Offers Future Growth OpportunitiesMultiple late-stage and earlier pipeline programs provide longer-term opportunities beyond current marketed products. Progress toward several clinical milestones can broaden Neurocrine’s therapeutic reach and create additional sources of growth if development and regulatory outcomes remain favorable.
Bears Say
Acquisition Reduced Liquidity And Increased Near-term CostsThe transaction materially changed Neurocrine’s liquidity profile and introduces significant integration, transaction, and purchase-accounting costs. Although the company reports no debt, the lower cash balance reduces financial flexibility and places greater importance on sustained operating cash generation.
VYKAT XR Launch Remains UnevenVYKAT XR adds scale but its contribution is not yet consistently accelerating. Early discontinuations, salesforce optimization, and ongoing integration may create variability in product revenue and earnings, making the acquired asset’s durable commercial contribution dependent on improved retention and execution.
Medium-term Earnings Uncertainty From Policy And Pipeline OutcomesNeurocrine faces uncertainty from possible future pricing changes affecting INGREZZA and from the cost of preparing successful pipeline assets for commercialization. These factors could pressure margins or create episodic SG&A increases, making earnings progression less predictable.
Neurocrine News
0K6R FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest share price was $118.72 and its highest was $190.00 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $14.37B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Nov 02, 2026 which is in 20 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Jul 30, 2026. The company reported $1.39 earnings per share for the quarter, missing the consensus estimate of $1.649 by -$0.259.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 0.32%. See more information on Neurocrine dividends here
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 1.91.
How many shares outstanding does Neurocrine have?
Neurocrine has 101,649,180 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1.39 in its last earnings report, missing expectations of $1.649. Following the earnings report the stock price went down -7.688%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in GB:0K6R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurocrine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$207.28 (34.61% Upside)
$207.28 (34.61% Upside)
Blogger Sentiment
Bullish
GB:0K6R Sentiment 77%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.46%
12-Months-Change
Fundamentals
Return on Equity
21.13%
Trailing 12-Months
Asset Growth
37.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Neurocrine
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
0K6R Company Deck
0K6R Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution and significant growth: near-record quarterly sales, raised INGREZZA guidance, sustained CRENESSITY launch momentum, immediate accretion from the VYKAT XR acquisition, and a deep pipeline with material Phase 3 catalysts in 2027. Key negatives are near-term GAAP headwinds and cash use from the ~$2.9B acquisition, early-stage launch variability and discontinuations for VYKAT XR, and lingering policy/pipeline outcome uncertainties that could create EPS variability. Overall, the positive operational and pipeline developments outweigh the transitional and financial integration challenges.View all GB:0K6R earnings summaries0K6R Stock 12 Month Forecast
Average Price Target
$207.28
▲(34.61% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Xenon
―
Axsome Therapeutics
―
Harmony Biosciences Holdings
―
Praxis Precision Medicines
―